Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vibrio vulnificus (lactose-positive vibrio) and Vibrio parahaemolyticus differ in their susceptibilities to human serum.

Literature DB >> 6788703

Vibrio vulnificus (lactose-positive vibrio) and Vibrio parahaemolyticus differ in their susceptibilities to human serum.

Abstract

Eleven Vibrio vulnificus (lactose-positive vibrio) strains were less susceptible to the bactericidal activity of normal human serum or serum treated with magnesium-ethyleneglycol-bis (beta-aminoethyl ether)-N,N'-tetraacetic acid than were six Vibrio parahaemolyticus strains.

Entities: Chemical Species

Mesh：

Substances：
Egtazic Acid

Year: 1981 PMID： 6788703 PMCID： PMC351537 DOI： 10.1128/iai.32.2.964-966.1981

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

8 in total

1. Bactericidal reaction of mouse serum.

Authors: L H MUSCHEL; T MUTO
Journal: Science Date: 1956-01-13 Impact factor: 47.728

2. A STUDY OF THE RELATIONSHIP OF THE NORMAL BACTERICIDAL ACTIVITY OF HUMAN SERUM TO BACTERIAL INFECTION.

Authors: R J Roantree; L A Rantz
Journal: J Clin Invest Date: 1960-01 Impact factor: 14.808

3. C3 shunt activation in human serum chelated with EGTA.

Authors: D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal: J Immunol Date: 1972-10 Impact factor: 5.422

4. Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae.

Authors: I Ingwer; B H Petersen; G Brooks
Journal: J Lab Clin Med Date: 1978-08

5. Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver.

Authors: J Fierer; F Finley
Journal: J Clin Invest Date: 1979-05 Impact factor: 14.808

6. Disease caused by a marine Vibrio. Clinical characteristics and epidemiology.

Authors: P A Blake; M H Merson; R E Weaver; D G Hollis; P C Heublein
Journal: N Engl J Med Date: 1979-01-04 Impact factor: 91.245

7. Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation.

Authors: R B Polhill; S L Newman; K M Pruitt; R B Johnston
Journal: J Immunol Date: 1978-07 Impact factor: 5.422

8. Experimental pathogenicity and mortality in ligated ileal loop studies of the newly reported halophilic lactose-positive Vibrio sp.

Authors: M D Poole; J D Oliver
Journal: Infect Immun Date: 1978-04 Impact factor: 3.441

8 in total

17 in total

1. Pulsed-field gel electrophoresis and ribotype profiles of clinical and environmental Vibrio vulnificus isolates.

Authors: M L Tamplin; J K Jackson; C Buchrieser; R L Murphree; K M Portier; V Gangar; L G Miller; C W Kaspar
Journal: Appl Environ Microbiol Date: 1996-10 Impact factor: 4.792

2. High-frequency phase variation of Vibrio vulnificus 1003: isolation and characterization of a rugose phenotypic variant.

Authors: Brenda L Grau; Margaret C Henk; Gregg S Pettis
Journal: J Bacteriol Date: 2005-04 Impact factor: 3.490

3. Molecular factors associated with virulence of marine vibrios isolated from striped bass in Chesapeake Bay.

Authors: A E Toranzo; J L Barja; S A Potter; R R Colwell; F M Hetrick; J H Crosa
Journal: Infect Immun Date: 1983-03 Impact factor: 3.441

Review 4. The human pathogenic vibrios--a public health update with environmental perspectives.

Authors: P A West
Journal: Epidemiol Infect Date: 1989-08 Impact factor: 2.451

Review 5. Current perspectives on the epidemiology and pathogenesis of clinically significant Vibrio spp.

Authors: J M Janda; C Powers; R G Bryant; S L Abbott
Journal: Clin Microbiol Rev Date: 1988-07 Impact factor: 26.132

6. Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.

Authors: S J Devi; U Hayat; J L Powell; J G Morris
Journal: Infect Immun Date: 1996-06 Impact factor: 3.441

7. Protection of mice against Vibrio vulnificus disease by vaccination with surface antigen preparations and anti-surface antigen antisera.

Authors: A S Kreger; L D Gray; J Testa
Journal: Infect Immun Date: 1984-09 Impact factor: 3.441